Chargement en cours...
Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model
CLSI and EUCAST susceptibility breakpoints for voriconazole and Candida albicans differ by one dilution (≤0.125 and ≤0.06 mg/liter, respectively) whereas the epidemiological cutoff values for EUCAST (ECOFF) and CLSI (ECV) are the same (0.03 mg/liter). We therefore determined the pharmacokinetic/phar...
Enregistré dans:
| Publié dans: | Antimicrob Agents Chemother |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society for Microbiology
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7269500/ https://ncbi.nlm.nih.gov/pubmed/32229492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00170-20 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|